Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.
Learn More
Alfa Cytology is dedicated to studying the mechanisms of drug resistance in leukemia and providing effective strategies to overcome it. With our extensive experience in leukemia drug development and our professional team, we are well-equipped to offer solutions for combating leukemia drug resistance. We offer targeted scientific research services aimed at overcoming drug resistance in leukemia specifically related to targeted therapy.
Drug resistance in leukemia refers to the phenomenon where leukemia cells become resistant to the effects of certain drugs or therapies that are initially effective in treating the disease. Drug resistance can occur through various mechanisms, including genetic mutations, altered drug metabolism, activation of survival pathways, and microenvironment influence. Drug resistance is the key to the failure of leukemia treatment.
Fig. 1. Leukemia cells can acquire drug resistance via genetic adaptation mechanisms.
Drug resistance occurs when cancer cells do not respond to drugs that would normally be able to kill or weaken them. Resistance may be present before treatment or may emerge during or after treatment. Alfa Cytology provides comprehensive drug resistance-related services, including but not limited to the following.
We provide services for gene mutation research, expression analysis of drug resistance-related miRNAs, analysis of signal pathways, and overexpression studies of drug resistance-related enzymes. Our services will help to understand the mechanisms of drug resistance and pave the way for innovative approaches to treating drug resistance in leukemia.
| Our Services | Descriptions |
|---|---|
Acute Myeloid Leukemia |
We provide design and development of novel FLT3 inhibitors, targeting alternative sites to overcome drug resistance caused by FLT3 gene mutations (ITD or TKD) in leukemia. Our services also include developing combination therapies involving IDH inhibitors to overcome AML resistance. Strategies encompass combining IDH inhibitors with chemotherapeutic agents, hypomethylating agents , and BCL-2 inhibitors. |
Chronic Myelogenous Leukemia |
We design BCR-ABL tyrosine kinase inhibitors targeting the kinase domain, allosteric site, and substrate site to overcome BCR-ABL-dependent resistance. Our tyrosine kinase inhibitor development services indirectly target BCR-ABL, addressing resistance by focusing on factors like transcription factors, aurora kinases, protein synthesis, signaling pathways, the bone marrow microenvironment, and mRNA transcripts. |
Acute Lymphoblastic Leukemia |
Our development services primarily revolve around the innovative creation of CAR-T and monoclonal antibody therapies. These advancements aim to replace the conventional targeting of CD19 or CD22 in acute lymphoblastic leukemia, presenting fresh outlooks in the realm of targeted immunotherapy. |
Chronic Lymphocytic Leukemia |
We aid in determining the ideal sequence of BTK inhibitors, PI3K inhibitors, and BCL-2 inhibitors tailored to your requirements. Our expertise enables strategic approaches to conquer drug resistance and improve treatment results. We provide services in developing bispecific antibodies and CAR T cell therapies for chronic lymphocytic leukemia therapy. |
Alfa Cytology understands the critical challenge of drug resistance in leukemia treatment. Our services are specifically tailored to address drug resistance and provide innovative solutions for overcoming this obstacle. For more information regarding our services, please do not hesitate to contact us.